ANIK - Anika Therapeutics Inc Stock Price, Fair Value and News

25.40USD-0.10 (-0.39%)Delayed

Market Summary

USD25.40-0.10

Delayed

-0.39%

ANIK Alerts

Big jump in Earnings (Y/Y)

Losses in recent quarter

ANIK Stock Price

View Fullscreen

ANIK RSI Chart

ANIK Valuation

Market Cap

376.6M

Price/Earnings (Trailing)

-4.9

Price/Sales (Trailing)

2.23

EV/EBITDA

-4.32

Price/Free Cashflow

-90.93

ANIK Price/Sales (Trailing)

ANIK Profitability

EBT Margin

-45.96%

Return on Equity

-36.84%

Return on Assets

-29.13%

Free Cashflow Yield

-1.1%

ANIK Fundamentals

ANIK Revenue

Revenue (TTM)

169.3M

Rev. Growth (Yr)

6.85%

Rev. Growth (Qtr)

-5.7%

ANIK Earnings

Earnings (TTM)

-76.8M

Earnings Growth (Yr)

56.39%

Earnings Growth (Qtr)

92.83%

Breaking Down ANIK Revenue

Last 7 days

-0.9%

Last 30 days

-1.1%

Last 90 days

4.9%

Trailing 12 Months

-2.2%

How does ANIK drawdown profile look like?

ANIK Financial Health

Current Ratio

5.59

Debt/Equity

0.12

Debt/Cashflow

0.07

ANIK Investor Care

Shares Dilution (1Y)

0.48%

Diluted EPS (TTM)

-5.25

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2024	169.3M	0	0	0
2023	157.5M	162.1M	163.3M	166.7M
2022	150.2M	151.7M	152.4M	156.2M
2021	129.4M	136.8M	144.7M	147.8M
2020	125.3M	125.5M	127.5M	130.5M
2019	109.0M	108.9M	111.8M	114.6M
2018	111.3M	108.4M	108.0M	105.6M
2017	104.5M	111.4M	112.8M	113.4M
2016	99.8M	103.4M	105.5M	103.4M
2015	87.1M	83.7M	85.4M	93.0M
2014	93.8M	99.3M	103.6M	105.6M
2013	72.2M	73.4M	76.4M	75.1M
2012	67.4M	70.9M	67.2M	71.4M
2011	54.8M	56.5M	61.1M	64.8M
2010	0	45.3M	50.4M	55.6M
2009	0	0	0	40.1M

Get all data in R, Python etc through our Historical Stock Data APIs

GRUFITY'S FAIR VALUE MODEL

Stocks Marked 'Very Cheap' by Grufity's Fair Value Model Have Outperformed Russell 2000 Index

Small Caps and Mid Caps are mostly overlooked by investors as all the focus goes to Magnificent 7. These stocks that are not part of the beauty contest require a deeper look. However, all large cap stocks were once small caps. Grufity's Fair Value model opens up this unverse as it separates high-performing, rewarding stocks from low-performing risky stocks. <b>Russell 2000 stocks that were marked 'Very Cheap' by the model doubled in three years while the index was flat.</b>

Returns of $10,000 invested in:

Very Cheap Stocks: $21,859
Russell 2000 Index: $10,334
Very Expensive Stocks: $8,224

Russell 2000 stocks considered 'Very Cheap' by the model greatly outperformed Russell 2000 index and the 'Very Expensive' bucket over past three years.

Russell 2000 Index

Very Expensive Stocks

Very Cheap Stocks

Try For Just $1.99

Tracking the Latest Insider Buys and Sells of Anika Therapeutics Inc

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Mar 11, 2024	blanchard cheryl r	acquired	-	-	64,480	president, ceo, director
Mar 11, 2024	nunes anne	sold (taxes)	-44,000	25.5818	-1,720	svp, chief operations officer
Mar 11, 2024	nunes anne	acquired	-	-	5,856	svp, chief operations officer
Mar 11, 2024	levitz michael l	acquired	-	-	19,201	evp, cfo, treasurer
Mar 11, 2024	colleran david	acquired	-	-	16,809	evp, general counsel, corp sec
Mar 11, 2024	levitz michael l	sold (taxes)	-144,284	25.5913	-5,638	evp, cfo, treasurer
Mar 11, 2024	colleran david	sold (taxes)	-126,306	25.5887	-4,936	evp, general counsel, corp sec
Mar 11, 2024	blanchard cheryl r	sold (taxes)	-716,629	25.6122	-27,980	president, ceo, director
Oct 01, 2023	nunes anne	acquired	-	-	2,491	svp, chief operations officer
Oct 01, 2023	nunes anne	sold (taxes)	-13,637	18.63	-732	svp, chief operations officer

Which funds bought or sold ANIK recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
May 16, 2024	Virtus Investment Advisers, Inc.	unchanged	-	124,887	1,157,710	0.83%
May 16, 2024	COMERICA BANK	unchanged	-	247	2,286	-%
May 16, 2024	CALIFORNIA STATE TEACHERS RETIREMENT SYSTEM	reduced	-38.9	-17,199	37,389	-%
May 16, 2024	JANE STREET GROUP, LLC	reduced	-45.92	-147,710	227,381	-%
May 15, 2024	QUADRANT CAPITAL GROUP LLC	added	58.28	5,719	13,107	-%
May 15, 2024	Aquatic Capital Management LLC	sold off	-100	-84,000	-	-%
May 15, 2024	D. E. Shaw & Co., Inc.	reduced	-9.31	63,552	3,898,620	-%
May 15, 2024	Meros Investment Management, LP	added	240	3,189,380	4,321,230	1.93%
May 15, 2024	BARCLAYS PLC	reduced	-26.36	-150,000	708,000	-%
May 15, 2024	AMERIPRISE FINANCIAL INC	reduced	-67.89	-1,785,420	1,003,910	-%

Are Funds Buying or Selling ANIK?

Are funds buying ANIK calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own ANIK

No. of Funds

Unveiling Anika Therapeutics Inc's Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Apr 05, 2024	blackrock inc.	10.7%	1,561,112	SC 13G/A
Mar 06, 2024	caligan partners lp	9.7%	1,423,493	SC 13D/A
Feb 13, 2024	vanguard group inc	5.22%	764,045	SC 13G/A
Feb 09, 2024	dimensional fund advisors lp	5.6%	821,452	SC 13G/A
Feb 09, 2024	trigran investments, inc.	14.6%	2,139,054	SC 13G/A
Jan 24, 2024	blackrock inc.	9.5%	1,383,877	SC 13G/A
Jan 22, 2024	state street corp	2.11%	309,041	SC 13G/A
Oct 06, 2023	blackrock inc.	9.7%	1,416,135	SC 13G/A
Sep 11, 2023	caligan partners lp	7.4%	1,081,360	SC 13D/A
Aug 17, 2023	caligan partners lp	6.2%	902,086	SC 13D

Recent SEC filings of Anika Therapeutics Inc

View All Filings

Date Filed	Form Type	Document
May 08, 2024	10-Q	Quarterly Report
May 08, 2024	8-K	Current Report
May 08, 2024	8-K	Current Report
Apr 26, 2024	10-K/A	Annual Report
Apr 05, 2024	SC 13G/A	Major Ownership Report
Mar 19, 2024	4	Insider Trading
Mar 19, 2024	4	Insider Trading
Mar 19, 2024	4	Insider Trading
Mar 19, 2024	4	Insider Trading
Mar 15, 2024	10-K	Annual Report

Peers (Alternatives to Anika Therapeutics Inc)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
ABT	181.0B	40.3B	-1.75%	-4.07%	32.18	4.49	-2.84%	-3.08%
BDX	68.3B	19.7B	1.78%	-6.05%	51.24	3.46	4.82%	-17.56%
ALGN	20.4B	3.9B	-9.57%	-7.50%	44.2	5.22	5.72%	46.72%
BAX	18.0B	14.9B	-10.73%	-18.01%	6.79	1.21	2.98%	207.68%
MID-CAP
ATR	9.8B	3.5B	6.68%	24.08%	31.27	2.76	6.16%	35.06%
HSIC	9.6B	12.5B	6.31%	-2.51%	24.63	0.77	-0.61%	-18.83%
BIO	8.4B	2.6B	1.13%	-22.65%	-26.02	3.22	-6.25%	-68.62%
XRAY	5.9B	3.9B	-6.79%	-30.12%	-62.84	1.49	0.23%	91.03%
AXNX	3.4B	387.1M	0.52%	31.17%	-216.3	8.9	30.82%	65.57%
PDCO	2.3B	6.6B	0.19%	-5.50%	11.93	0.35	2.78%	-0.87%
SMALL-CAP
AHCO	1.3B	3.2B	5.94%	-10.00%	-1.91	0.41	7.94%	-1661.78%
ANIK	376.6M	169.3M	-1.13%	-2.23%	-4.9	2.23	7.49%	-244.90%
ANGO	241.9M	324.0M	-4.58%	-37.15%	-1.26	0.75	-3.19%	-337.41%
APYX	56.1M	50.5M	22.73%	-73.49%	-2.46	1.11	14.25%	-10.06%
AEMD	1.0M	3.7M	-71.13%	32.26%	-0.09	0.28	5.77%	8.23%

Anika Therapeutics Inc News

Latest updates

Anika Therapeutics Inc Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

Income Statement (Quarterly)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Revenue	-5.7%	40,523,000	42,971,000	41,465,000	44,302,000	37,924,000	39,622,000	40,264,000	39,657,000	36,693,000	35,821,000	39,536,000	38,145,000	34,292,000	32,688,000	31,694,000	30,678,000	35,397,000	29,772,000	29,697,000	30,418,000	24,723,000
Gross Profit	-6.5%	24,628,000	26,329,000	24,944,000	28,972,000	22,843,000	24,131,000	22,779,000	24,862,000	21,804,000	18,134,000	23,023,000	20,812,000	20,974,000	16,745,000	17,343,000	13,742,000	21,197,000	21,123,000	23,746,000	23,582,000	17,412,000
Costs and Expenses	-67.1%	29,691,000	90,110,000	32,618,000	32,603,000	35,396,000	30,798,000	28,577,000	28,243,000	25,358,000	27,257,000	21,723,000	11,632,000	19,716,000	34,697,000	25,270,000	23,278,000	14,103,000	-3,777,000	17,648,000	18,503,000	19,241,000
S&GA Expenses	5.9%	21,527,000	20,335,000	24,827,000	23,689,000	26,996,000	23,049,000	21,276,000	21,268,000	19,201,000	20,432,000	17,500,000	17,989,000	18,175,000	15,179,000	15,903,000	14,550,000	14,431,000	12,237,000	7,539,000	7,502,000	7,672,000
R&D Expenses	7.6%	8,164,000	7,585,000	7,791,000	8,914,000	8,400,000	7,749,000	7,301,000	6,975,000	6,157,000	6,000,000	7,673,000	7,293,000	6,361,000	7,632,000	5,217,000	4,532,000	6,050,000	4,084,000	4,158,000	4,165,000	4,258,000
EBITDA Margin	11.1%	-0.42	-0.47	-0.13	-0.13	-0.13	-0.08	-0.10	-0.05	0.03	0.06	0.00	-0.10	-	-	-	-	-	-	-	-	-
Income Taxes	124.1%	43,000	-178,500	-463,000	-300,000	-1,700,000	-1,470,500	-1,187,000	-442,000	-800,000	-3,404,000	694,000	2,600,000	-1,600,000	-2,503,000	-1,700,000	-1,997,000	1,580,000	1,117,500	3,331,000	3,000,000	1,473,000
Earnings Before Taxes	92.9%	-4,471,000	-63,204,000	-7,039,000	-3,070,000	-12,014,000	-6,391,000	-5,362,000	-3,285,000	-3,708,000	-9,170,000	1,252,000	9,130,000	1,215,000	-18,137,000	-8,155,000	-9,705,000	7,373,000	5,162,000	12,531,000	12,448,000	5,980,000
EBT Margin	10.2%	-0.46	-0.51	-0.17	-0.17	-0.17	-0.12	-0.14	-0.10	-0.02	0.02	-0.05	-0.12	-	-	-	-	-	-	-	-	-
Net Income	92.8%	-4,514,000	-63,000,000	-6,576,000	-2,741,000	-10,350,000	-4,908,000	-4,175,000	-2,843,000	-2,933,000	-5,793,000	558,000	6,531,000	2,838,000	-15,657,000	-6,411,000	-7,708,000	5,793,000	4,051,000	9,200,000	9,435,000	4,507,000
Net Income Margin	8.5%	-0.45	-0.50	-0.15	-0.14	-0.14	-0.10	-0.10	-0.07	-0.01	0.03	-0.04	-0.09	-	-	-	-	-	-	-	-	-
Free Cashflow	-207.6%	-1,934,000	1,798,000	5,744,000	-9,750,000	-5,007,000	-2,048,000	1,018,000	1,148,000	-3,195,000	3,345,000	778,000	1,979,000	-	-	-	-	-	-	-	-	-

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet																					(In Millions)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Assets	-2.5%	264	271	328	329	339	349	348	354	342	348	353	363	362	366	416	441	399	331	320	287	307
Current Assets	-2.7%	159	163	157	152	160	170	168	168	165	169	166	178	173	177	202	221	161	234	224	190	210
Cash Equivalents	-5.8%	69.00	73.00	71.00	65.00	80.00	86.00	88.00	91.00	90.00	94.00	91.00	97.00	95.00	96.00	104	117	66.00	157	103	69.00	96.00
Inventory	6.5%	49.00	46.00	44.00	43.00	41.00	40.00	37.00	35.00	35.00	36.00	35.00	43.00	43.00	46.00	48.00	46.00	43.00	22.00	25.00	23.00	23.00
Net PPE	-0.3%	46.00	46.00	46.00	48.00	49.00	48.00	47.00	48.00	48.00	48.00	49.00	50.00	49.00	51.00	52.00	53.00	54.00	51.00	52.00	53.00	53.00
Goodwill	-2.2%	7.00	8.00	7.00	7.00	7.00	7.00	7.00	7.00	8.00	8.00	8.00	8.00	8.00	8.00	32.00	34.00	34.00	8.00	7.00	8.00	8.00
Current Liabilities	-8.4%	28.00	31.00	28.00	23.00	29.00	28.00	26.00	29.00	27.00	30.00	29.00	41.00	47.00	37.00	31.00	28.00	26.00	16.00	11.00	10.00	12.00
Long Term Debt	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	25.00	50.00	-	-	-	-	-
LT Debt, Non Current	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	25.00	50.00	-	-	-	-	-
Shareholder's Equity	-1.8%	209	212	270	274	278	286	285	286	286	287	290	287	277	272	284	288	294	288	282	251	269
Retained Earnings	-3.5%	124	128	191	198	200	211	216	220	223	226	231	231	224	221	237	244	251	245	241	232	223
Additional Paid-In Capital	1.3%	91.00	90.00	86.00	82.00	83.00	81.00	77.00	73.00	69.00	67.00	64.00	61.00	57.00	55.00	53.00	51.00	48.00	49.00	46.00	24.00	52.00
Accumulated Depreciation	-100.0%	-	48.00	-	-	-	46.00	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Shares Outstanding	1.1%	15.00	15.00	15.00	15.00	15.00	15.00	15.00	15.00	14.00	14.00	14.00	14.00	-	-	-	-	-	-	-	-	-
Float	-	-	-	-	370	-	-	-	322	-	-	-	620	-	-	-	531	-	-	-	570	-

Cashflow (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Cashflow (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Cashflow From Operations	-103.5%	-126	3,638	6,485	-8,293	-3,618	481	2,709	3,088	-1,869	4,472	2,062	4,294	-2,431	2,587	5,865	3,568	1,045	13,022	10,051	5,470	8,462
Share Based Compensation	-5.9%	3,590	3,815	3,561	4,150	3,717	3,813	3,876	4,081	2,545	3,166	2,863	2,797	2,259	1,433	1,920	2,240	-207	1,947	1,311	1,443	1,386
Cashflow From Investing	1.7%	-1,808	-1,840	-741	-1,457	-1,389	-2,529	-1,691	-1,940	-1,326	-1,240	-1,295	-2,317	1,734	16,809	6,729	-2,299	-92,503	41,024	2,100	-1,516	-1,917
Cashflow From Financing	-764.6%	-2,273	342	-110	-4,943	-1,613	667	-4,611	-46.00	-862	60.00	-6,982	594	-451	-28,112	-25,179	49,658	-141	278	21,699	-30,000	-119
Buy Backs	-	-	-	-	5,050	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	30,000	-

Get Full Access to Grufity – and Unlimited Downloads

Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.

Try For Just $1.99

ANIK Income Statement

2024-03-31

Condensed Consolidated Statements of Operations and Comprehensive Income (Unaudited) - USD ($) shares in Thousands, $ in Thousands	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Revenue	$ 40,523	$ 37,924
Cost of revenue	15,895	15,081
Gross Profit	24,628	22,843
Operating Expenses:
Research and development	8,164	8,400
Selling, general and administrative	21,527	26,996
Total operating expenses	29,691	35,396
Loss from operations	(5,063)	(12,553)
Interest and other income (expense), net	592	539
Loss before income taxes	(4,471)	(12,014)
Provision for (benefit from) income taxes	43	(1,664)
Net loss	$ (4,514)	$ (10,350)
Net loss per share:
Basic (in dollars per share)	$ (0.31)	$ (0.71)
Diluted (in dollars per share)	$ (0.31)	$ (0.71)
Weighted average common shares outstanding:
Basic (in shares)	14,698	14,653
Diluted (in shares)	14,698	14,653
Net loss	$ (4,514)	$ (10,350)
Foreign currency translation adjustment	(372)	272
Comprehensive loss	$ (4,886)	$ (10,078)

ANIK Balance Sheet

2024-03-31

Condensed Consolidated Balance Sheets (Current Period Unaudited) - USD ($) $ in Thousands	Mar. 31, 2024	Dec. 31, 2023
Current assets:
Cash and cash equivalents	$ 68,629	$ 72,867
Accounts receivable, net	32,077	35,961
Inventories, net	49,408	46,386
Prepaid expenses and other current assets	8,848	8,095
Total current assets	158,962	163,309
Property and equipment, net	46,057	46,198
Right-of-use assets	28,181	28,767
Other long-term assets	17,571	18,672
Deferred tax assets	1,273	1,489
Intangible assets, net	4,297	4,626
Goodwill	7,403	7,571
Total assets	263,744	270,632
Current liabilities:	10,022	9,860
Accrued expenses and other current liabilities	18,438	21,199
Total current liabilities	28,460	31,059
Other long-term liabilities	404	404
Lease liabilities	26,344	26,904
Commitments and contingencies (Note 9)
Common stock, $0.01 par value; 90,000 shares authorized, 15,009 issued and 14,821 outstanding and 14,848 issued and 14,660 outstanding at March 31, 2024 and December 31, 2023, respectively	148	147
Preferred stock, $0.01 par value; 1,250 shares authorized, no shares issued and outstanding at March 31, 2024 and December 31, 2023, respectively	0	0
Additional paid-in-capital	91,165	90,009
Accumulated other comprehensive loss	(6,315)	(5,943)
Retained earnings	123,538	128,052
Total stockholders’ equity	208,536	212,265
Total liabilities and stockholders’ equity	$ 263,744	$ 270,632

About Anika Therapeutics Inc

Anika Therapeutics, Inc., a joint preservation company, creates and delivers advancements in early intervention orthopedic care in the areas of osteoarthritis (OA) pain management, regenerative solutions, sports medicine, and bone preserving joint solutions in the United States, Europe, and internationally. The company develops, manufactures, and commercializes products based on hyaluronic acid (HA) technology platform. Its OA pain management products includes Monovisc and Orthovisc, an injectable HA-based viscosupplement for the pain relief from osteoarthritis conditions; Cingal, a single-injection OA pain management product to provide both short- and long-term pain relief; and Hyvisc, a molecular weight injectable HA veterinary product. The company's joint preservation and restoration product family comprises 150 bone preserving joint technology products, including partial joint replacement, joint resurfacing, and invasive and bone sparing implants, which are designed to treat upper and lower extremity orthopedic conditions; sports medicine solutions used to repair and reconstruct damaged ligaments and tendons; and orthopedic regenerative solutions, including Hyalofast and Tactoset. In addition, it offers non-orthopedic products comprising HA-based products for non-orthopedic applications including adhesion barrier, advanced wound care, ear, nose, and throat products, as well as ophthalmic products. The company was founded in 1983 and is headquartered in Bedford, Massachusetts.

CEO	Dr. Cheryl Renee Blanchard Ph.D.
WEBSITE	anikatherapeutics.com
INDUSTRY	Medical Instruments & Supplies
EMPLOYEES	345

Anika Therapeutics Inc Frequently Asked Questions

What is the ticker symbol for Anika Therapeutics Inc? What does ANIK stand for in stocks?

ANIK is the stock ticker symbol of Anika Therapeutics Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Anika Therapeutics Inc (ANIK)?

As of Fri May 17 2024, market cap of Anika Therapeutics Inc is 376.64 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of ANIK stock?

You can check ANIK's fair value in chart for subscribers.

What is the fair value of ANIK stock?

You can check ANIK's fair value in chart for subscribers. The fair value of Anika Therapeutics Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Anika Therapeutics Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for ANIK so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Anika Therapeutics Inc a good stock to buy?

The fair value guage provides a quick view whether ANIK is over valued or under valued. Whether Anika Therapeutics Inc is cheap or expensive depends on the assumptions which impact Anika Therapeutics Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for ANIK.

What is Anika Therapeutics Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Fri May 17 2024, ANIK's PE ratio (Price to Earnings) is -4.9 and Price to Sales (PS) ratio is 2.23. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. ANIK PE ratio will change depending on the future growth rate expectations of investors.

What is 5 year return on Anika Therapeutics Inc's stock?

In the past 10 years, Anika Therapeutics Inc has provided -0.059 (multiply by 100 for percentage) rate of return.